MULTIPURPOSE ARTHRITIS & MUSCULOSKELETAL DISEASE CENTER

这是一份多功能关节炎的续期申请， 肌肉骨骼疾病中心（MAMDC）。 中心带来 一起在风湿性关节炎的医疗和卫生服务的研究活动 疾病在四个机构在圣地亚哥地区：大学 加州圣地亚哥斯克里普斯研究所索尔克 生物研究所和拉荷亚过敏研究所 和免疫学（L.J.I.A.I）。 生物医学研究部分 MAMDC要求为五个创新发展项目提供资金， 和可行性项目有关的基本发病机制 风湿病 私家侦探，M. Croft，（L.J.I.A.I.）将决定 CD 4淋巴细胞亚群在发育和 类风湿性关节炎动物模型的研究进展。私家侦探，L. 冯，（斯克里普斯）将剖析化学引诱蛋白质的作用， IL-8和MCP-1在实验性关节炎中的作用 私家侦探，D.绿色， （L.J.I.A.I.）将测试新的假设，即体细胞突变， p53可导致类风湿性滑膜P.I.中的异常凋亡， C.里维耶，（索尔克）将分析之间的关系 下丘脑激素促肾上腺皮质激素释放因子， 促炎细胞因子肿瘤坏死因子a，在实验性 关节炎 私家侦探，国会议员，Corr（UCSD）将使用基因疗法， 调节抗原特异性免疫应答，而不诱导 全身免疫抑制 教育、流行病学和 卫生服务研究（EEHSR）部分包括两个 注重健康结果评估的建议， 风湿性疾病患者的经济后果。 EEHSR项目1 P.I.，T，Ganiats，（UCSD）将确定是否 患者以类似的方式对关节炎的健康结果进行折扣， 财政资源，并将调查是否病人 风湿性疾病患者更喜欢近期的好处，而不是长期的好处。 后果 下一个项目，PI，R.卡普兰，（UCSD）将使用 一种新的自我管理的幸福质量（QWB）量表， 测量慢性肌肉骨骼疾病患者的健康结果 疾病 MAMDC的生物医学和EEHSR组件 将由三个核心支持。 行政（H.G.布鲁斯坦， 主任）将提供全面指导和评价， MAMDC通过一个执行委员会，由一个外部机构协助 咨询委员会：它将提供日常管理和 所有MAMDC项目的临床专业知识。分子生物学 核心人员（陈宝培主任）将促进及时利用 分子生物学技术的医生和科学家在 中心，并将指导一个共享的仪器设施。 的 生物统计学核心（C.Berry，主任）将提供咨询， 中心的调查人员，并将成立一个新的遗传流行病学 以关节炎和肌肉骨骼为重点的全球网站 紊乱

This is a renewal application for a Multipurpose Arthritis and Musculoskeletal Disease Center (MAMDC). The Center brings together medical and health services research activities in rheumatic diseases at four institutions in the San Diego area: the University of California, San Diego, The Scripps Research Institute, the Salk Institute for Biological Studies, and the LaJolla Institutes for Allergy and Immunology (L.J.I.A.I). The Biomedical Research Component of the MAMDC requests funding for five innovative developmental and feasibility projects related to the fundamental etiopathogenesis of rheumatic disease. P.I., M. Croft, (L.J.I.A.I.) Will determine the importance of CD4 lymphocyte subsets in the development and progression of an animal model of rheumatoid arthritis. P.I., L. Feng, (Scripps) will dissect the role of the chemoattractant proteins IL-8 and MCP-1 in experimental arthritis. P.I., D. Green, (L.J.I.A.I.) will test the novel hypothesis that somatic mutations of p53 can lead to aberrant apoptosis in the rheumatoid synovium P.I., C. Rivier, (Salk) will analyze the relationship between the hypothalamic hormone corticotrophin releasing factor, and the proinflammatory cytokine tumor necrosis factor a, in experimental arthritis. P.I., M.P., Corr (UCSD) will use gene therapy to modulate antigen-specific immune responses, without inducing general immunosuppression. The Education, Epidemiology, and Health Services Research (EEHSR) Component encompasses two proposals that focus on health outcome assessments, and their economic consequences, in patients with rheumatic diseases. EEHSR Project 1 P.I., T, Ganiats, (UCSD) will determine if patients discount health outcomes in arthritis in a manner analogous to financial resources, and will investigate whether or not patients with rheumatic diseases prefer near-term benefits to far-term consequences. The next Project, P.I., R. Kaplan, (UCSD) will use a new self-administered quality of well-being (QWB) scale to measure health outcome in patients with chronic musculoskeletal diseases. The Biomedical and EEHSR components of the MAMDC will be supported by three cores. Administration (H.G. Bluestein, Director) will provide overall direction and evaluation of the MAMDC through an Executive Committee assisted by an Outside Advisory Committee: and it will provide day-to-day management and clinical expertise for all MAMDC projects. The Molecular Biology Core (P.P. Chen, Director) will facilitate the timely utilization of molecular biology techniques by physicians and scientists in the Center, and will direct a shared instrumentation facility. The Biostatistics Core (C.Berry, Director) will provide consultation to Center investigators, and will set up a new genetic epidemiology world-wide web site with a focus on arthritis and musculoskeletal disorders.